Financial Data and Key Metrics Changes - For the full year 2025, the company generated revenue of $2.9 billion, reflecting a year-over-year decline driven by unfavorable pricing and mix, and lower volumes in both TiO2 and zircon [12] - Loss from operations was $253 million, and net loss attributable to Tronox was $470 million, including $233 million of restructuring and other charges [13] - Adjusted EBITDA was $336 million, with an adjusted EBITDA margin of 11.6% [13] Business Line Data and Key Metrics Changes - TiO2 volumes in Q4 reached their highest point of the year, with a 9% increase in volumes, although prices declined by 4% [14] - Zircon revenues increased 32% sequentially, driven by a 42% increase in volumes, despite a 7% decline in price [15] - Revenue from other products increased 10% year-over-year, mainly due to higher pig iron volumes [15] Market Data and Key Metrics Changes - The company experienced market share gains in India, Latin America, and the Middle East, supported by anti-dumping measures [14] - North America and Europe saw lower volumes consistent with normal fourth quarter demand patterns [14] - The company noted a structural change in global TiO2 trade flows, particularly benefiting from anti-dumping duties [7] Company Strategy and Development Direction - The company is focused on cash generation and maintaining liquidity, with capital expenditures expected to be approximately $260 million in 2026 [20] - Tronox is implementing a sustainable cost improvement program, targeting $125 million-$175 million in run rate savings by the end of 2026 [10] - The company is advancing its rare earth strategy, aiming to move downstream into separated rare earth oxides while maintaining capital discipline [26] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about market dynamics improving, with TiO2 prices expected to rise due to recent price increase announcements [11] - The company anticipates positive free cash flow in 2026, supported by improved pricing and cost management initiatives [12] - Management highlighted the importance of maintaining a disciplined approach to cash preservation and inventory management [8] Other Important Information - The company executed a $400 million senior secured note offering in September to increase liquidity [8] - The company closed two pigment plants to streamline operations and improve cost structure [9] Q&A Session Summary Question: Free cash flow guidance and EBITDA expectations - The company indicated that to reach breakeven, approximately $350 million in EBITDA is needed, with expectations for EBITDA to expand throughout the year [28][31] Question: Production costs and mining operations - Management clarified that while some production costs were positively impacted in Q4, they expect improvements in operations and efficiencies in Q1 [36][37] Question: Volume changes in TiO2 and industry contraction - The company confirmed a slight decline in TiO2 volumes year-over-year, with the global TiO2 industry experiencing similar trends [58][59] Question: Pricing dynamics and industry discipline - Management noted that the industry is seeing price increases announced across the board, indicating a potential shift towards price discipline [84][85]

Core Viewpoint - The company is focused on executing high-level commercial and financial strategies while aiming for growth in 2029 and 2030 [1]. Group 1: Financial Performance and Strategy - The company has made significant progress in delivering on its financial promises [1]. - A total of $7.7 billion in cost improvements have been identified to enhance the cost structure over the next several years [2]. - The company is strategically rightsizing its operations in anticipation of a period of Loss of Exclusivity (LOE) [2].

Financial Data and Key Metrics Changes - The company achieved net sales of approximately $178 million for Q3 2025, with organic sales for strategic segments up 10% year-over-year [5][6] - Adjusted diluted earnings per share were $0.22, with adjusted EBITDA of $20 million and an adjusted gross margin of 52.8% [6][18] - Full-year revenue estimates have been raised to $690-$700 million, and adjusted EPS estimates have been raised to $0.85-$0.95 per share [6][19] Business Line Data and Key Metrics Changes - The Specialty Nutrition Systems (SNS) segment grew organically by 14.5% year-over-year, driven by strong demand for enteral feeding products [11] - The Pain Management and Recovery segment saw normalized organic sales increase by 2.4%, with double-digit growth in the radio frequency ablation business [13][16] - The hyaluronic acid injections and intravenous infusion product lines declined over 20% due to the divestiture of the HA business [16] Market Data and Key Metrics Changes - The SNS segment's operating profit improved to 20%, reflecting higher sales volume despite tariff impacts [12] - The Pain Management and Recovery segment's operating profit was 3%, a 200 basis point improvement year-over-year [16] Company Strategy and Development Direction - The company aims to accelerate growth in strategic segments, manage tariff impacts, improve operational efficiencies, divest underperforming assets, and pursue synergistic acquisitions [4][6] - The acquisition of Nexus Medical is expected to be immediately accretive to revenue growth and earnings per share, expanding the company's presence in a $70 million market [7][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in addressing tariff impacts and enhancing the company's growth profile despite challenges [21] - The company anticipates generating approximately $25-$30 million of free cash flow for the year, factoring in one-time charges related to transformation efforts [18][30] Other Important Information - The company is prioritizing supply chain investments to exit China by mid-2026, which will result in higher-than-anticipated capital expenditures in 2025 [10] - The company has maintained a strong balance sheet with $70 million in cash and $103 million in debt, keeping leverage levels below one turn [17] Q&A Session Summary Question: Details on the cost improvement plan and annualized cost savings - Management explained that the $15 million-$20 million in annualized cost savings will be realized by the end of 2026 through streamlining the organization and improving decision-making [24][25] Question: Insights on the product development pipeline - Management indicated a shift to a hybrid model for product development, combining internal projects with external contracting to improve speed to market [26][27] Question: Appetite for more M&A deals - Management confirmed an appetite for more synergistic M&A opportunities, particularly in the Specialty Nutrition Systems business, while actively seeking such opportunities [28][29] Question: Clarification on free cash flow assumptions - Management clarified that the $25 million-$30 million free cash flow estimate includes charges related to transformation efforts and higher capital expenditures for the China exit plan [30]